Tempest Therapeutics, Inc. TPST · SEC Filings

4

Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedic...

Price0.3614

Market Cap7.2 M

Float10.93 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Tempest Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice

Nov 5, 2026

8-K

Tempest Therapeutics Announces Resignation of CFO Constance Ames and Appointment of Stephanie Horn-Warnock

Oct 30, 2026

8-K

Special Meeting Adjourned Again Over Insufficient Votes on Proposal to Enable Stockholder Action by Written Consent

Oct 20, 2026

8-K

Tempest Appoints John W. Frederick to Board of Directors

Oct 19, 2026

8-K

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

Sep 28, 2026

8-K

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

Sep 17, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Oct 2, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 8,910,579

Sep 1, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 2,426,897 | Bank: H.C. Wainwright & Co., LLC

Jul 8, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 2,777,781

Apr 10, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 8,268,495

Apr 10, 2026

424B5

REGISTERED OFFERING

Nov 25, 2025

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

3

Horn-Warnock Stephanie (Reporting)

Nov 3, 2026

4

Frederick John W. (Reporting)

Nov 2, 2026

3

Frederick John W. (Reporting)

Nov 2, 2026

4

Smith Nancy Freda (Reporting)

Oct 2, 2026

3

Smith Nancy Freda (Reporting)

Oct 2, 2026

S-3

Form S-3 - Registration statement under Securities Act of 1933

Sep 25, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 2, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 1, 2026

CORRESP

Form CORRESP - Correspondence

Aug 27, 2026

LETTER

Form UPLOAD - SEC-generated letter

Aug 27, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 8, 2026

CORRESP

Form CORRESP - Correspondence

Jul 2, 2026